New Enterprise Associates related stories
All articles and analysis
Top VC deals done in Canada in third quarterCanada’s Venture Capital and Private Equity Association and research partner Thomson Reuters will in November publish their full report on Canadian venture capital activity in the third quarter of 2014. In the meantime, peHUB Canada has compiled an early list of some of the top disclosed financings completed between July and September.
Accel leads funding round of data visualization company ZoomdataZoomdata, which provides a platform to analyze data, announced the close of a $17 million Series B round of funding. New investor Accel Partners led the round, which included returning investors New Enterprise Associates, Columbus Nova Technology Partners, Razor’s Edge Ventures and B7. As part of the funding, Jake Flomenberg, general partner at Accel, has joined the board. Reston, Virginia-based Zoomdata has now raised $22.2 million in total funding.
- VCs get smart on edtech
Pragmatic investors enroll more dollars in edtech. Top VCs talk about their strategies.
White boarding the education spaceSeveral top VCs talk about their edtech strategies
Desire2Learn makes global e-learning pushAugust financing comes at a time when investment activity in Canada is showing continued growth
- Houzz snags $165 mln in Sequoia-led round
Palo Alto, Calif.-based home remodeling and design platform Houzz has secured $165 million in funding. Sequoia led the round with participation from Oren Zeev, New Enterprise Associates, GGV Capital, Kleiner Perkins Caufield & Byers, DST Global and T. Rowe Price.
- VC-backed Interlude names president and COO
Interlude, a New York-based digital media company that designs, develops and markets interactive video technology, has hired Jim Spare as president and chief operating officer. Spare is the former CEO of Canesta. Interlude's backers include Sequoia Capital, Intel Capital, NEA, Marker and Innovation Endeavors.
- Adaptimmune raises $104 million to develop immune-system cancer drugs-Reuters
British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells, Reuters reported.
- Tracon Pharmaceuticals racks up $27 mln Series B
Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo Securities were placement agents for the financing. In addition to the funding, Paul Walker of NEA has been added to Tracon's board of directors while Bruce Steel of BioMed Ventures will become a board observer. Based in San Diego, Tracon develops treatments for cancer and age-related macular degeneration.